Literature DB >> 33917774

Skin Manifestation of SARS-CoV-2: The Italian Experience.

Gerardo Cazzato1, Caterina Foti2, Anna Colagrande1, Antonietta Cimmino1, Sara Scarcella1, Gerolamo Cicco1, Sara Sablone3, Francesca Arezzo4, Paolo Romita2, Teresa Lettini1, Leonardo Resta1, Giuseppe Ingravallo1.   

Abstract

At the end of December 2019, a new coronavirus denominated Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was identified in Wuhan, Hubei province, China. Less than three months later, the World Health Organization (WHO) declared coronavirus disease-19 (COVID-19) to be a global pandemic. Growing numbers of clinical, histopathological, and molecular findings were subsequently reported, among which a particular interest in skin manifestations during the course of the disease was evinced. Today, about one year after the development of the first major infectious foci in Italy, various large case series of patients with COVID-19-related skin manifestations have focused on skin specimens. However, few are supported by histopathological, immunohistochemical, and polymerase chain reaction (PCR) data on skin specimens. Here, we present nine cases of COVID-positive patients, confirmed by histological, immunophenotypical, and PCR findings, who underwent skin biopsy. A review of the literature in Italian cases with COVID-related skin manifestations is then provided.

Entities:  

Keywords:  COVID-19; Italian; SARS-CoV-2; WHO; manifestation; skin

Year:  2021        PMID: 33917774     DOI: 10.3390/jcm10081566

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  6 in total

1.  SARS-CoV-2, Placental Histopathology, Gravity of Infection and Immunopathology: Is There an Association?

Authors:  Leonardo Resta; Antonella Vimercati; Gerardo Cazzato; Margherita Fanelli; Sara Vincenza Scarcella; Giuseppe Ingravallo; Anna Colagrande; Sara Sablone; Mary Stolfa; Francesca Arezzo; Teresa Lettini; Roberta Rossi
Journal:  Viruses       Date:  2022-06-18       Impact factor: 5.818

Review 2.  Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations.

Authors:  Andrea Marino; Antonio Munafò; Egle Augello; Carlo Maria Bellanca; Carmelo Bonomo; Manuela Ceccarelli; Nicolò Musso; Giuseppina Cantarella; Bruno Cacopardo; Renato Bernardini
Journal:  Infect Dis Rep       Date:  2022-05-11

3.  Early Evidence of Circulating SARS-CoV-2 in Unvaccinated and Vaccinated Measles Patients, September 2019-February 2020.

Authors:  Joana Paixao; Maria Galangue; Celestina Gaston; Raísa Carralero; Celestina Lino; Gracieth Júlio; Zinga David; Moises Francisco; Cruz S Sebastião; Euclides N M Sacomboio; Joana Morais; Ngiambudulu M Francisco
Journal:  Infect Drug Resist       Date:  2022-02-19       Impact factor: 4.003

4.  Newly diagnosed Glioblastoma Multiforme (GBM) during COVID-19 pandemic: changes in therapeutic approach to minimize in-hospital SARS-COV-2 contagion in pre-vaccine era.

Authors:  Valeria Internò; Roberta Rudà; Maria Chiara Sergi; Riccardo Soffietti; Camillo Porta
Journal:  Acta Biomed       Date:  2022-07-01

Review 5.  SARS-CoV-2 and Skin: New Insights and Perspectives.

Authors:  Gerardo Cazzato; Eliano Cascardi; Anna Colagrande; Caterina Foti; Alessandra Stellacci; Maricla Marrone; Giuseppe Ingravallo; Francesca Arezzo; Vera Loizzi; Antonio Giovanni Solimando; Paola Parente; Eugenio Maiorano; Gennaro Cormio; Angelo Vacca; Leonardo Resta
Journal:  Biomolecules       Date:  2022-08-31

Review 6.  Nutrition as Personalized Medicine against SARS-CoV-2 Infections: Clinical and Oncological Options with a Specific Female Groups Overview.

Authors:  Miriam Dellino; Eliano Cascardi; Marina Vinciguerra; Bruno Lamanna; Antonio Malvasi; Salvatore Scacco; Silvia Acquaviva; Vincenzo Pinto; Giovanni Di Vagno; Gennaro Cormio; Raffaele De Luca; Miria Lafranceschina; Gerardo Cazzato; Giuseppe Ingravallo; Eugenio Maiorano; Leonardo Resta; Antonella Daniele; Daniele La Forgia
Journal:  Int J Mol Sci       Date:  2022-08-15       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.